What changed: Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)
Every dated change on the records linked to Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2024 · 1
2021 · 6
- 2021GuidelineLocoregionally advanced nasopharyngeal carcinoma (stage III to IVA)Guideline CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers: After chemoradiotherapy
Metronomic capecitabine for one year in high-risk patients; EBV DNA-directed adjuvant therapy in trials (NRG-HN001).
- 2021GuidelineLocoregionally advanced nasopharyngeal carcinoma (stage III to IVA)Guideline CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers: Follow-up
Plasma EBV DNA, MRI and nasopharyngoscopy; management of xerostomia, hearing loss, hypothyroidism and hypopituitarism.
- 2021GuidelineLocoregionally advanced nasopharyngeal carcinoma (stage III to IVA)Guideline CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers: Immunotherapy in the curative setting
PD-1 antibody (sintilimab in CONTINUUM; toripalimab and camrelizumab in trials) added to induction and chemoradiotherapy in high-risk disease, adopted in China.
- 2021GuidelineLocoregionally advanced nasopharyngeal carcinoma (stage III to IVA)Guideline CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers: Stage III to IVA, standard
Induction gemcitabine and cisplatin for three cycles followed by intensity-modulated radiotherapy (70 Gy) with concurrent cisplatin; TPF induction as an alternative.
- 2021GuidelineLocoregionally advanced nasopharyngeal carcinoma (stage III to IVA)Guideline CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers: Staging
MRI of the nasopharynx and neck, PET-CT or CT of chest and abdomen with bone scan, plasma EBV DNA, dental and audiological assessment.
- 2021MilestoneCapecitabineMetronomic adjuvant capecitabine improves failure-free survival; CSCO-ASCO guideline published
A milestone in how this cancer is treated.